These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33747424)

  • 1. Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation.
    Li PH; Lin CH; Lin YH; Chen TC; Hsu CY; Teng CJ
    Ther Adv Hematol; 2021; 12():2040620721998124. PubMed ID: 33747424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.
    Fukuda M; Hattori J; Ohkubo R; Watanabe A; Maekawa S
    Clin Drug Investig; 2024 Jul; 44(7):527-540. PubMed ID: 38935253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia.
    Lin CH; Su YJ; Hsu CY; Wang PN; Teng CJ
    Transpl Infect Dis; 2019 Aug; 21(4):e13096. PubMed ID: 31004545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
    Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
    Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
    Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation.
    Li WW; Zhang YM; Shen MZ; Mo XD
    Blood Sci; 2024 Jan; 6(1):e00178. PubMed ID: 38213825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
    Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
    Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study.
    Studer U; Khanna N; Leuzinger K; Hirsch HH; Heim D; Lengerke C; Tsakiris DA; Halter J; Gerull S; Passweg J; Medinger M; Gwerder M
    Anticancer Res; 2020 Oct; 40(10):5909-5917. PubMed ID: 32988922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis.
    Moore WJ; Boutin CA; Tanna S
    Curr Opin Infect Dis; 2023 Dec; 36(6):514-521. PubMed ID: 37773928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.
    Jerry Teng CL; Wang PN; Chen YC; Ko BS
    J Microbiol Immunol Infect; 2021 Jun; 54(3):341-348. PubMed ID: 33514495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
    Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
    Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review.
    El Helou G; Razonable RR
    Infect Drug Resist; 2019; 12():1481-1491. PubMed ID: 31239725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.
    Talaya A; Giménez E; Vinuesa V; Pérez A; Amat P; Piñana JL; Albert E; Hernández-Boluda JC; Solano C; Navarro D
    Med Microbiol Immunol; 2019 Aug; 208(3-4):405-414. PubMed ID: 30911925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
    Winstead RJ; Kumar D; Brown A; Yakubu I; Song C; Thacker L; Gupta G
    Transpl Infect Dis; 2021 Aug; 23(4):e13570. PubMed ID: 33469975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letermovir Effectively Prevents Cytomegalovirus Infection in Patients with Aplastic Anemia After Hematopoietic Stem Cell Transplantation: A Real-World Retrospective Cohort Study.
    Zhang Y; Chen X; Zhou M; Zhang Y; Chen C; Zhou R; Li Y; Yang F; Xu S; Wang C; Zhou W; Deng T; Pan S; Mo W; Wang S
    Infect Dis Ther; 2024 Feb; 13(2):345-359. PubMed ID: 38265628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus antiviral resistance among participants in the phase 3 trial of letermovir vs valganciclovir prophylaxis in kidney transplant recipients.
    Strizki JM; Diamond TL; Teal VL; Gilbert CL; Wang W; Stauffer N; Haber B
    J Infect Dis; 2024 Jun; ():. PubMed ID: 38853607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.